The impact of medical therapy on surgery for benign prostatic hyperplasia: A study comparing changes in a decade (1992-2002)

BJU International

Volumn 96, Issue 7, 2005, Pages 1045-1048

  Vela Navarrete, Remigio ^a,b   Gonzalez Enguita, Carmen ^a   Garcia Cardoso, Juan V ^a   Manzarbeitia, Felix ^a   Sarasa Corral, Jose Luis ^a   Granizo, Juan José ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

BPH; Medical therapy; Surgery

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; FINASTERIDE; PLANT EXTRACT; STEROID 5ALPHA REDUCTASE INHIBITOR;

AGED; BLOOD TRANSFUSION; COMORBIDITY; EPIDIDYMITIS; HEALTH STATUS; HEMATURIA; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PHYTOTHERAPY; POSTOPERATIVE COMPLICATION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PROSTATE DISEASE; PROSTATE HYPERTROPHY; RETROSPECTIVE STUDY; REVIEW; TRANSURETHRAL RESECTION; TREATMENT OUTCOME;

ADENOMA; ADRENERGIC ALPHA-ANTAGONISTS; AGE FACTORS; AGED; CHI-SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; ENZYME INHIBITORS; FINASTERIDE; HUMANS; MALE; MIDDLE AGED; PATIENT SELECTION; PHYTOTHERAPY; PROSTATE; PROSTATECTOMY; PROSTATIC HYPERPLASIA; RETROSPECTIVE STUDIES; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 27444441020     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2005.05735.x     Document Type: Review

References (22)

1. Vela-Navarrete R, Garcia-Cardoso J, Castillon-Vela I et al. BPH progression. Are patients now operated older and with larger adenomas?. Eur Urol 2002; 41 (Suppl. 1): A670, 170
2. Lu-Yao GL, Barry MJ, Chang CH, Wasson JH, Wennberg JE. Transurethral resection of the prostate among Medicare beneficiaries in the United States: time trends and outcomes. Prostate Patient Outcome Research Team (PORT). Urology 1994; 44: 692-8
3. Guschin BL, Jones CA, Nyberg LM. Decline in the surgical treatment of benign prostatic hyperplasia (BPH) from 1985 to 1994. J Urol 1997; 157: 311, A1211
4. Borth CS, Beiko DT, Nickel JC. Impact of medical therapy on transurethral resection of the prostate: a decade of change. Urology 2001; 57: 1082-5
5. McNicholas TA. Management of symptomatic BPH in the UK: who is treated and how? Eur Urol 1999; 36 (Suppl. 3): 33-9
6. Clifford GM, Farmer RD. Medical therapy for benign prostatic hyperplasia: a review of the literature. Eur Urol 2000; 38:2-19
7. Mebust WK, Holtgrewe HL, Cockett AT, Peters PC. Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients. J Urol 1989; 141: 243-7
8. Ornstein DK, Rao GS, Smith DS, Andriole GL. The impact of systematic prostate biopsy on prostate cancer incidence in men with symptomatic benign prostatic hyperplasia undergoing transurethral resection of the prostate. J Urol 1997; 157: 880-4
9. Holtgrewe HL, Mebust WK, Dowd JB, Cockett AT, Peters PC, Proctor C. Transurethral prostatectomy: practice aspects of the dominant operation in American urology. J Urol 1989; 141: 248-353
10. Flanigan RC, Reda DJ, Wasson RJ, Anderson RJ, Abdellatif MN, Bruskewitz RC. 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs cooperative study. J Urol 1998; 160: 12-7
11. Jacobsen SJ, Jacobsen DJ, Girman CJ et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol 1997; 158: 481-7
12. McConnell JD, Bruskewitz R, Walsh P et al. The effect of Finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 1998; 338: 557-63
13. Djavan B, Marberger M. A meta-analysis on the efficacy and tolerability of alpha1-adrenoreceptor antagonist in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999; 36: 1-13
14. Chapple C. Alpha blockade. In Chapple CR, McConnell JD, Tubaro A eds, BPH: Current Therapy. London: Martin Dunits, 2000: 1-26
15. Wei JT, Schottenfeld D, Cooper K et al. The natural history of lower urinary tract symptoms in black American men: relationships with aging, prostate size, flow rate and bothersomeness. J Urol 2001; 165: 1521-5
16. Moore E, Bracken B, Bremner W et al. Proscar: five-year experience. Eur Urol 1995; 28: 304-9
17. Roehrborn CG, Bruskewitz R, Nickel GC et al. Urinary retention in patients with BPH treated with finasteride or placebo over 4 years. Characterisation of patients and ultimate outcomes. The PLESS Study Group. Eur Urol 2000; 37: 528-36
18. Boyle P, Gould AL, Roehrborn GC. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 1996; 48: 398-405
19. McConnell JD. The long effects of medical therapy on the progression on BPH; Results from the MTOPS trial. J Urol 2002; 167 (Suppl. 4): 265, A1042
20. Borboroglu PG, Kane CJ, Ward JF, Roberts JL, Sands JP. Immediate and postoperative complications of transurethral resection of the prostate in the 1990s. J Urol 1999; 162: 1307-10
21. Fourcade RO, Vallancien G. Morbidity of endoscopie prostatic resection: 3-month prospective study. Practical Urology Club. Prog Urol 2000; 10: 48-52
22. Uchida T, Ohori M, Soh S et al. Factors influencing morbidity in patients undergoing transurethral resection of the prostate. Urology 1999; 53: 98-105